Risks and benefits of antiarrhythmics need to be defined Newsletter Article 15 February 2013 Pages: 2 - 2
He who shouts loudest - shifting from Rx to OTC status Ian Mundell Newsletter Article 15 February 2013 Pages: 3 - 3
More patients with atrial fibrillation should receive anticoagulants Newsletter Article 15 February 2013 Pages: 4 - 4
An innovative alternative to randomised controlled trials Newsletter Article 15 February 2013 Pages: 6 - 6
Cortisol schedule influences QOL in Addison’s disease Newsletter Article 15 February 2013 Pages: 7 - 7
Antihyperglycaemic efficacy of acidic guanidines demonstrated Newsletter Article 15 February 2013 Pages: 8 - 8
The ‘postantibiotic era’ - are vaccines the way to curb pneumococcal disease? Gill Higgins Newsletter Article 15 February 2013 Pages: 9 - 10
Positive inotrope confusion helped by classification system Newsletter Article 15 February 2013 Pages: 10 - 10
The future for potassium channel activators in asthma Newsletter Article 15 February 2013 Pages: 11 - 11
Single-dose pamidronic acid for malignant hypercalcaemia Newsletter Article 15 February 2013 Pages: 13 - 13
Potential role for octreotide in Cushing’s syndrome Newsletter Article 15 February 2013 Pages: 13 - 13
Think of combination therapy in HIV-infected children Newsletter Article 15 February 2013 Pages: 14 - 14
Chloroquine/proguanil still effective antimalarial prophylaxis Newsletter Article 15 February 2013 Pages: 14 - 14
Audit identifies avoidable death in younger people Newsletter Article 15 February 2013 Pages: 15 - 15
Disappointing results with interferon in subfoveal neovascularisation Newsletter Article 15 February 2013 Pages: 15 - 15
Normal growth possible for Down’s syndrome children Newsletter Article 15 February 2013 Pages: 15 - 15
Further factors to consider in theophylline dosing Newsletter Article 15 February 2013 Pages: 19 - 19